Christopher D. O’Brien

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

Bruce E. Sands, William J. Sandborn, Remo Panaccione et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration

Gaoyuan Cao, Christopher D. O’Brien, Zhou Zhao et al. · American Journal of Physiology-Cell Physiology · 2002 · 219 citations

Life Sciences, Cell Biology, Oncology +17

Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study

Bruce E. Sands, William J. Sandborn, Brian G. Feagan et al. · Journal of Crohn s and Colitis · 2018 · 115 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

William J. Sandborn, Brian G. Feagan, Silvio Danese et al. · Inflammatory Bowel Diseases · 2020 · 115 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

Antibodies Against the First Ig-Like Domain of Human Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) That Inhibit PECAM-1-Dependent Homophilic Adhesion Block In Vivo Neutrophil Recruitment

Marian T. Nakada, Kunjlata M. Amin, Melpo Christofidou‐Solomidou et al. · The Journal of Immunology · 2000 · 110 citations

Life Sciences, Cell Biology, Immunology +17